Related Experiment Video
Updated: Feb 27, 2026
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Antibody Therapeutics: Bench to Bedside
1Pharmaceuticals and Medical Devices Agency (PMDA).
Abstract:
Monoclonal antibodies have been considered promising therapeutic entities due to their highly specific binding to antigens. For oncology in particular, the tumor specific binding of an antibody, without affecting normal tissue, is considered an ideal cancer therapy. Although the proposed mechanism of action of antibody therapeutics varies by targets and indications, antibody-dependent cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), ligand neutralization and inhibition of the signaling pathway are commonly used. Recent advances in genomic information, genetic engineering, and transgenic technology have greatly accelerated drug development processes. It is also possible to add new functions to antibody molecules through molecular engineering. For example, antibody-drug conjugates (ADC), which combine a monoclonal antibody and a small-molecule cytotoxic drug, have been successfully used for cancer treatment. It has been more than 20 years since the first therapeutic antibody was approved in Japan, and there are now more than 30 antibodies on the market, with many new molecules under development. Despite some drawbacks and challenges, antibody therapeutics hold great promise as we advance our knowledge and technologies in the coming years.
Insights
Monoclonal antibodies offer targeted cancer therapy by binding to tumor cells. Advances in engineering, like antibody-drug conjugates (ADCs), enhance their effectiveness, promising future oncology treatments.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Monoclonal antibodies are highly specific therapeutic agents.
- Targeted binding to tumor cells offers an ideal cancer therapy approach.
- Antibody therapeutics utilize mechanisms like antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Purpose of the Study:
- To review the development and therapeutic potential of monoclonal antibodies in oncology.
- To highlight advancements in antibody engineering and their impact on cancer treatment.
- To discuss the current landscape and future promise of antibody therapeutics.
Main Methods:
- Review of scientific literature on monoclonal antibody development and applications.
- Analysis of mechanisms of action for antibody-based cancer therapies.
- Examination of technological advancements, including antibody-drug conjugates (ADCs).
Main Results:
- Over 30 therapeutic antibodies are currently approved, with many more in development.
- Molecular engineering enables new functionalities, exemplified by successful ADCs.
- Significant progress in genomic information and genetic engineering accelerates drug discovery.
Conclusions:
- Monoclonal antibodies represent a promising frontier in cancer therapy.
- Continued advancements in technology and understanding will overcome current challenges.
- Antibody therapeutics hold substantial promise for future oncology treatments.
More Related Videos
Related Concept Videos
00:42Cross-reactivity
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
01:26Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:10Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
01:36Humoral Immune Responses